Paper Details

  1. Home
  2. Paper Details

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Author: AntoszykAndrew N, CiullaThomas A, DreyerRichard F, GentileRonald C, HantsbargerGary, HeierJeffrey S, LeffSteven R, PavanPeter Reed, RosenfeldPhilip J, ShamsNaveed, SyJudy P

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Repeated intravitreal injections of ranibizumab had a good safety profile and were associated with improved VA and decreased leakage from choroidal neovascularization in subjects with neovascular AMD.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess safety of repeated intravitreal injections of ranibizumab in treating neovascular age-related macular degeneration (AMD), and to assess changes in visual acuity (VA) and AMD lesion characteristics. DESIGN: Multicenter, controlled, open-label, clinical trial. PARTICIPANTS: Sixt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ophtha.2005.10.052

データ提供：米国国立医学図書館（NLM）

Ranibizumab: A New Hope for Neovascular Age-Related Macular Degeneration

This study explores the safety and efficacy of ranibizumab, a novel therapeutic agent, in treating neovascular age-related macular degeneration (AMD). The study involved a multi-center, controlled trial involving 64 patients with subfoveal AMD-related choroidal neovascularization. The results indicate that repeated intravitreal injections of ranibizumab had a favorable safety profile and were associated with significant improvements in visual acuity (VA) and reduced leakage from choroidal neovascularization. The study also observed a reduction in subretinal fluid, suggesting that ranibizumab could effectively target the underlying mechanisms of neovascular AMD.

Ranibizumab: A Desert Oasis for Eye Health

This research offers hope for individuals battling neovascular AMD, highlighting the potential of ranibizumab to significantly improve vision and reduce leakage associated with this debilitating condition. Imagine an oasis in the desert, offering a source of fresh water and restoring sight – ranibizumab, like this oasis, can provide a glimmer of hope for those affected by neovascular AMD.

A New Path for AMD Treatment

This study, like a camel caravan discovering a new route through the desert, introduces a promising new approach to treating neovascular AMD. It highlights the potential of ranibizumab to significantly improve visual acuity and slow the progression of this debilitating condition.

Dr.Camel's Conclusion

This study underscores the potential of ranibizumab as a valuable treatment option for neovascular AMD. Like a camel caravan navigating a vast and challenging desert, researchers are continually searching for innovative solutions to treat this debilitating condition, and ranibizumab offers a promising new path toward restoring vision and improving the quality of life for patients.
Date :
  1. Date Completed 2006-04-11
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

16483659

DOI: Digital Object Identifier

10.1016/j.ophtha.2005.10.052

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.